Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00SJE
|
|||
| Former ID |
DAP000674
|
|||
| Drug Name |
Secobarbital
|
|||
| Synonyms |
Barbosec; Evronal; Hypotrol; Hyptran; Meballymal; Meballymalum; Pramil; Quinalbarbital; Quinalbarbitone; Secobarbitale; Secobarbitalum; Secobarbitone; Seconal; Seotal; Somosal; Secobarbital solution; Secobarbital suppository dosage form; Secobarbitale [DCIT]; Secobarbital [USAN:INN]; Secobarbitalum [INN-Latin]; Seconal (TN);Secobarbital (USP/INN); (+-)-5-Allyl-5-(1-methylbutyl)-barbituric acid; (+-)-Secobarbital; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)-, (+-)-(9CI); 5-(1-methylbutyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-(pentan-2-yl)-5-(prop-2-en-1-yl)-pyrimidine-2,4,6(1H,3H,5H)-trione; 5-ALLYL-5-(1-METHYLBUTYL)BARBITURIC ACID; 5-Allyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Allyl-5-(1-methylbutyl)barbiturate; 5-Allyl-5-(1-methylbutyl)malonylurea; 5-allyl-5-(1-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-pentan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Intractable insomnia [ICD-11: 7A00; ICD-10: F51.0] | Approved | [1] | |
| Therapeutic Class |
Hypnotics and Sedatives
|
|||
| Company |
Eli Lilly
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H18N2O3
|
|||
| Canonical SMILES |
CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C
|
|||
| InChI |
1S/C12H18N2O3/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)
|
|||
| InChIKey |
KQPKPCNLIDLUMF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 76-73-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
4505086, 6492744, 7847496, 7980445, 8153189, 10535334, 11533864, 15196371, 24899481, 24899579, 29224251, 46508708, 49873712, 49873713, 57322645, 57654604, 57654614, 75816069, 81065615, 103165830, 104308529, 117425384, 124954080, 125310254, 125662946, 126634473, 128420595, 134971831, 134996021, 137101289, 138744653, 142971002, 144239027, 162224594, 179226084, 180372431, 223365950, 224779910, 226459714, 236330815, 241138157, 250049256
|
|||
| ChEBI ID |
CHEBI:9073
|
|||
| ADReCS Drug ID | BADD_D01997 ; BADD_D01998 | |||
| SuperDrug ATC ID |
N05CA06
|
|||
| SuperDrug CAS ID |
cas=000076733
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | GABA(A) receptor alpha-1 (GABRA1) | Target Info | Antagonist | [2], [3] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Retrograde endocannabinoid signaling | ||||
| GABAergic synapse | ||||
| Morphine addiction | ||||
| Nicotine addiction | ||||
| Reactome | Ligand-gated ion channel transport | |||
| GABA A receptor activation | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | ||||
| Iron uptake and transport | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. | |||
| REF 3 | Effect of barbiturates on polyphosphoinositide biosynthesis and protein kinase C activity in synaptosomes. Neuropharmacology. 1989 Dec;28(12):1317-23. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.